知镜 Cognispect · 医学文献与研究工作台

Anti-neutrophil extracellular trap antibodies in autoimmune rheumatic diseases: a suitable biomarker of thrombosis in systemic lupus erythematosus.

Mancuso S, Rapino L, Riccieri V, Alessandri C, Spinelli FR, Ceccarelli F, Truglia S, Mohammed Reza Beigi D, Garufi C, Pecani A, Conti F.
Clinical and experimental rheumatology · 2026-05-18 · PMID 42154658

文献摘要

Objectives This case-control study aimed to elucidate the prevalence and role as biomarker of anti-neutrophil extracellular trap (anti-NET) antibodies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc). Methods Serum samples from SLE, RA, SSc and healthy donors (HD) were evaluated for anti-NETs IgG, using an ELISA home-made coated with phorbol myristate acetate (PMA)-induced NET. Based on a positivity threshold set at the 99th percentile for HD sera, we calculated the positive samples. Results We enrolled 349 patients with autoimmune rheumatic diseases (ARD), finding a prevalence of anti-NETs of about 40%. Of the 136 SLE patients 50 (36.8%) were anti-NETs positive, revealing an association between anti-NETs and antiphospholipid syndrome (APS) (OR 3.37 [95% CI 1.22-9.36], p=0.02) and with arterial thrombosis regardless of coexisting APS (OR 5.52 [95% CI 1.07-28.52], p=0.032). In RA patients 52 out 131 (39.7%) tested positive for anti-NETs and we found a significant association between testing positive for anti-NETs and the presence of ACPA (p=0.049). Of the 82 SSc patients enrolled 33 (40%) were anti-NETs positive, and we found a direct correlation with CCL-18 (r 0.289 [CI 95% 0.04-0.50], p=0.02), a biomarker of worst prognosis and mortality in ILD-SSc patients. Conclusions In SLE patients, anti-NETs could have a role as a biomarker of thrombosis, a major cause of mortality in SLE.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。